Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Invivoscribe

News headline image
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care
From Invivoscribe
Via Business Wire
News headline image
Invivoscribe Announces the PrepQuant™ System, an Integrated Sample Preparation Platform that Standardizes and Streamlines Pre-Analytical Workflows
From Invivoscribe
Via Business Wire
News headline image
Invivoscribe® Expands IVDR Portfolio with IdentiClone® Dx IGH Assay Certification
From Invivoscribe
Via Business Wire
News headline image
Invivoscribe® Launches LeukoStrat® KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide
From Invivoscribe
Via Business Wire
News headline image
LabPMM® Receives New York State Approval for the NPM1 MRD Assay - Informing Therapy and Accelerating Targeted Trials
From Invivoscribe
Via Business Wire
News headline image
Invivoscribe’s LabPMM Gains New York State Approval for the FLT3 ITD MRD Assay
From Invivoscribe
Via Business Wire
News headline image
Invivoscribe Announces Registration of the LeukoStrat® CDx FLT3 Mutation Assay in the United Kingdom and Switzerland
From Invivoscribe
Via Business Wire
News headline image
EU Notified Body (BSI Netherlands) and the EMA Grant Approval of the LeukoStrat® CDx FLT3 Mutation Assay for VANFLYTA® Therapy in the EU and EEA
From Invivoscribe
Via Business Wire
News headline image
Study Suggests Critical Link Between Residual FLT3-ITD Mutations in Remission and Post-Transplant Outcomes in AML
From Invivoscribe
Via Business Wire
News headline image
Invivoscribe Launches Grant Program to Support Novel Applications for Sequence-Based Analyses of the Immune System
From Invivoscribe
Via Business Wire
News headline image
Invivoscribe Premieres 12-Color Flow Cytometry Capabilities at their Reference Labs in the US, Europe, and China
From Invivoscribe
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.